DrugPatentWatch Database Preview

Details for Patent: 8,802,714

« Back to Dashboard

Which drugs does patent 8,802,714 protect, and when does it expire?

Patent 8,802,714 protects TPOXX and is included in one NDA.

This patent has twenty-eight patent family members in ten countries.

Summary for Patent: 8,802,714

Title:	Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Abstract:	Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.
Inventor(s):	Jordan; Robert F. (Corvallis, OR), Bailey; Thomas R. (Phoenixville, PA), Rippin; Susan R. (Wilmington, DE), Dai; Dongcheng (Corvallis, OR)
Assignee:	Siga Technologies, Inc. (Corvallis, OR)
Application Number:	13/966,392
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 8,802,714
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 8,802,714

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Siga Technologies	TPOXX	tecovirimat	CAPSULE;ORAL	208627-001	Jul 13, 2018		RX	Yes	Yes						TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG

International Family Members for US Patent 8,802,714

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004249250
Australia	2007351866
Canada	2529761
Canada	2685153
Canada	2685198